Published in Chest on January 01, 2000
Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol (2008) 1.69
The relationship between serum uric acid and spirometric values in participants in a health check: the Takahata study. Int J Med Sci (2011) 1.10
Laboratory and echocardiography markers in sickle cell patients with leg ulcers. Am J Hematol (2011) 0.89
Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study. Rheumatol Int (2010) 0.85
Could uric acid be a modifiable risk factor in subjects with pulmonary hypertension? Med Hypotheses (2010) 0.84
Relationship between serum uric acid levels and ventricular function in patients with idiopathic pulmonary hypertension. Exp Clin Cardiol (2013) 0.79
Obesity and pulmonary hypertension: a review of pathophysiologic mechanisms. J Obes (2012) 0.79
2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2014) 0.77
[Hyperuricemia - more than gout : Impact on cardiovascular risk and renal insufficiency]. Z Rheumatol (2015) 0.77
The association between risk of airflow limitation and serum uric acid measured at medical health check-ups. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Kidney dysfunction in patients with pulmonary arterial hypertension. Pulm Circ (2017) 0.75
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med (1991) 13.21
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Primary pulmonary hypertension. A national prospective study. Ann Intern Med (1987) 6.80
Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest (2000) 5.26
An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med (1992) 4.74
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med (2000) 4.07
Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med (2001) 3.92
Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol (1994) 3.83
Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J (2001) 3.20
Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J (2005) 2.83
Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J (2005) 2.82
Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol (2000) 2.73
Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest (1998) 2.54
Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest (1998) 2.37
Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest (1995) 2.30
Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest (1997) 2.29
Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol (2001) 2.24
Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med (1999) 2.21
Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation (1997) 2.03
Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res (2001) 2.00
Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest (1987) 1.96
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation (1982) 1.92
Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res (2001) 1.75
Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol (1999) 1.63
Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis (1990) 1.62
Hypoxia inducible factor-1α in human emphysema lung tissue. Eur Respir J (2010) 1.62
Proactive integrated care improves quality of life in patients with COPD. Eur Respir J (2009) 1.61
Operation Everest II: oxygen transport during exercise at extreme simulated altitude. J Appl Physiol (1985) (1988) 1.60
Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest (1999) 1.59
Nonimmunological production of leukotrienes induced by platelet-activating factor. Science (1982) 1.58
Macrophage proliferation in vitro induced by exudates. Nature (1975) 1.55
In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol (1998) 1.54
3D coronary reconstruction from routine single-plane coronary angiograms: clinical validation and quantitative analysis of the right coronary artery in 100 patients. Int J Card Imaging (2000) 1.51
Hypothyroidism and primary pulmonary hypertension: an autoimmune pathogenetic link? Ann Intern Med (1993) 1.51
Smooth muscle-mediated connective tissue remodeling in pulmonary hypertension. Science (1987) 1.47
Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol (1997) 1.46
Smaller alveolar-arterial O2 gradients in Tibetan than Han residents of Lhasa (3658 m). Respir Physiol (1996) 1.45
Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol (1985) (2001) 1.44
Operation Everest II: preservation of cardiac function at extreme altitude. J Appl Physiol (1985) (1987) 1.42
Severe pulmonary hypertension and arterial adventitial changes in newborn calves at 4,300 m. J Appl Physiol (1985) (1987) 1.40
Right ventricular ischemia and proximal right coronary artery narrowing indicated by exercise ST-segment elevation in lead V1. Am J Cardiol (1989) 1.38
Ventricular septal defect due to nonpenetrating chest trauma: use of the intra-aortic balloon pump. J Trauma (1987) 1.34
HOX genes in human lung: altered expression in primary pulmonary hypertension and emphysema. Am J Pathol (2001) 1.29
The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med (2001) 1.27
Pulmonary hypertension and inflammation. J Lab Clin Med (1998) 1.25
Operation Everest II: pulmonary gas exchange during a simulated ascent of Mt. Everest. J Appl Physiol (1985) (1987) 1.24
The pressure-overloaded right ventricle in pulmonary hypertension. Chest (1998) 1.24
The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis (1986) 1.21
5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med (1998) 1.18
The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis (1989) 1.16
Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med (2001) 1.16
Pulmonary hypertension in chronic liver disease. Clin Chest Med (1996) 1.15
Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest (1996) 1.14
Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol (1997) 1.13
Leukotriene C4 and D4 in neonates with hypoxemia and pulmonary hypertension. N Engl J Med (1983) 1.11
PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats. J Appl Physiol (1985) (1992) 1.10
Oxygen transport during steady-state submaximal exercise in chronic hypoxia. J Appl Physiol (1985) (1991) 1.10
Increased dependence on blood glucose after acclimatization to 4,300 m. J Appl Physiol (1985) (1991) 1.09
Are Tibetans better adapted? Int J Sports Med (1992) 1.09
Measurement of peptidoleukotrienes in biological fluids. J Appl Physiol (1985) (1990) 1.08
Muscle accounts for glucose disposal but not blood lactate appearance during exercise after acclimatization to 4,300 m. J Appl Physiol (1985) (1992) 1.08
Vasopressin-induced pulmonary vasodilation in rats. Am J Physiol (1989) 1.07
Rupture of left sinus of Valsalva aneurysm into the pulmonary artery. J Am Coll Cardiol (1985) 1.07
Alveolar inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension. Am J Physiol (1985) 1.06
Decreased reliance on lactate during exercise after acclimatization to 4,300 m. J Appl Physiol (1985) (1991) 1.05
Arterial catecholamine responses during exercise with acute and chronic high-altitude exposure. Am J Physiol (1991) 1.05
Analysis of 6-keto PGF1 alpha, 5-HETE, and LTC4 in rat lung: comparison of GM/MS, RIA, and EIA. Prostaglandins (1986) 1.03
Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patients. Kidney Int (1985) 1.02
Witnessing violence by young children and their mothers. J Dev Behav Pediatr (1994) 1.00
Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Am J Respir Crit Care Med (1998) 1.00
Leukotoxin, 9,10-epoxy-12-octadecenoate causes edematous lung injury via activation of vascular nitric oxide synthase. Am J Physiol (1995) 1.00
Aorto-coronary vein fistula. A complication of coronary artery bypass graft surgery. Chest (1981) 0.99
Restraining orders: a frequent marker of adverse maternal health. Pediatrics (1999) 0.99
Release of vasodilator prostaglandin, PGI2, from isolated rat lung during vasoconstriction. Circ Res (1981) 0.97
Thermodilution method overestimates low cardiac output in humans. Am J Physiol (1983) 0.96
Accuracy and reproducibility of new M-mode echocardiographic recommendations for measuring left ventricular dimensions. Circulation (1980) 0.95
Decreased exercise muscle lactate release after high altitude acclimatization. J Appl Physiol (1985) (1989) 0.95
Operation Everest II: cardiac filling pressures during cycle exercise at sea level. Respir Physiol (1990) 0.94
Decreased pulmonary vasoreactivity in an animal model of chronic Pseudomonas pneumonia. Am Rev Respir Dis (1990) 0.93
Magnesium toxicity as a cause of hypotension and hypoventilation. Occurrence in patients with normal renal function. Arch Intern Med (1985) 0.93
Oxygen transport and cardiovascular function at extreme altitude: lessons from Operation Everest II. Int J Sports Med (1992) 0.93
PAF antagonists: different effects on platelets, neutrophils, guinea pig ileum and PAF-induced vasodilation in isolated rat lung. Prostaglandins (1986) 0.92
Effects of hypoxia on density of beta-adrenergic receptors. J Appl Physiol Respir Environ Exerc Physiol (1981) 0.92
Cellular adaptation during chronic neonatal hypoxic pulmonary hypertension. Am J Physiol (1991) 0.92
Vascular remodeling in neonatal pulmonary hypertension. Role of the smooth muscle cell. Chest (1988) 0.91
Importance of angiotensin-converting enzyme in pulmonary hypertension. Cardiology (1995) 0.91
Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. Am J Respir Cell Mol Biol (1989) 0.91